Aptevo Therapeutics Inc. · NASDAQ:APVO
Aptevo Therapeutics — Investor Presentation (February 2025)
30 slides from Aptevo Therapeutics's investor presentation, Feb 11, 2025
Slide 1: Aptevo Therapeutics, 11 February 2025
CONFIDENTIAL 11, February 2025 | Nasdaq: APVO
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo's expectations about the activity, efficacy and
Slide 3: Aptevo Therapeutics: Bispecifics Differentiated by Design
Aptevo Therapeutics: Bispecifics Differentiated by Design Multi-Billion-Dollar Opportunities Assets that specifically target high-value oncology indications in multi-billion-dollar underserved markets Rationally Designed Assets Bispecifics that are engineered for optimal immune engagement delivering
Slide 4: Differentiated & Diversified Bispecifics Built to Overcome Common Safety Challenges
Combinable with standard of care or other experimental therapies (i.e. radioisotopes, antibody drug conjugates (ADC’s), adaptive T cells, checkpoint molecules, other bispecifics) CHO production cell lines used with antibody-like purification Aptevo’s Differentiated & Diversified Bispecifics Built to
Slide 5: Diversified Pipeline Offers Multiple Opportunities for Partnering
Diversified Pipeline Offers Multiple Opportunities for Partnering *mipletamig combined with standard of care venetoclax + azacitidine in unfit (unable to receive high dose chemotherapy) frontline AML patients **Partnered with Alligator Bioscience CLINICAL PROGRAMS PRE-CLINICAL PROGRAMS PROGRAM (Targ
Slide 6: Market Opportunity
Aptevo is developing multiple molecules capable of targeting hematologic and solid tumor malignancies with large market potential Market Opportunity Select Global Market Opportunities* Size AML/MDS/Other leukemias $6.3B Breast Cancer $32.1B Non-Small Cell Lung Cancer $24.2B Colorectal Cancer $15.8B
Slide 7: Mipletamig (CD3 x CD123 Bispecific) AML, MDS and Other Leukemias
Mipletamig (CD3 X CD123 Bispecific) AML, MDS and Other Leukemias “The mipletamig results are promising and show that it is well-suited to combine with the venetoclax + azacitidine standard of care regimen. We see a very manageable safety profile and promising efficacy, including duration of remissio
Slide 8: RAINIER Phase 1b/2 Trial: Dose Optimization
RAINIER Phase 1b/2 Trial: Part 1 Dose Optimization (Ongoing) Cohort 1 Highlights All patients achieved complete remission (CR), continuing efficacy trends seen in prior trials No CRS* was observed One CR patient had no minimal residual disease (MRD-negative status) One patient was positive for the T
Slide 9: Previous Trial Results Show Compelling Data
Previous Trial Results Show Compelling Data *CR, CRi, MLFS, PR or SD **In combination with standard of care venetoclax + azacitidine in venetoclax naïve patients ***Benchmark Composite References: Aldoss 2019, Maiti 2021, Morsia 2020, Garciaz 2022, Feld 2021 Combination Therapy Superiority Demonstra
Slide 10: Comparison of Mipletamig Clinical Results to Date
Comparison of Mipletamig Clinical Results to Date Promising frontline patient results in combination with Ven/Aza vs. benchmarks Mipletamig Ven/Aza-Viale-A (1) Pivekimab(2) Phase 1B 3 1B/2 # Patients 7 431 50 CR/CRi 100% 66% 68% CR 86% 37% 54% (1) Frontline benchmark: Viale A registrational trial -
Slide 11: AML Blast Reduction with Mipletamig
AML Blast Reduction with Mipletamig: Evidence of Single Agent Activity in the Dose Escalation Study Key Takeaways 1/2 of evaluable monotherapy patients (49%) experienced clinical benefit (CR, CRi, MLFS, PR or SD) (19 of 39 evaluable patients) More than 1/3 of evaluable monotherapy patients (36%) exp
Slide 12: ALG.APV-527 Multiple Solid Tumor Type Expressing 5T4
ALG.APV-527 Multiple Solid Tumor Type Expressing 5T4 ALG.APV-527 is differentiated from other solid tumor-targeting bispecifics because it combines precise tumor specificity (via 5T4 targeting) with controlled immune activation through 4-1BB stimuli. The drug candidate incorporates the innovative de
Slide 13: ALG.APV-527 Dose Escalation Trial Yields Positive Data
ALG.APV-527 Dose Escalation Trial Yields Positive Data Promising data from the ALG.APV-527 multi-center Phase 1 dose escalation trial, were reported as follows: Clinical activity | Signs of clinical activity were observed, 10 of 17 efficacy evaluable patients (59%) have a best overall response to da
Slide 14: Preclinical Pipeline & Platforms
Preclinical Pipeline & Platforms
Slide 15: Preclinical Pipeline: Novel, Solid Tumor-Targeted, Built for Safety
Preclinical Pipeline: Novel, Solid Tumor-Targeted, Built for Safety APV0711 APVO603 Diagram Mechanism of Action Dual mechanism of action designed to provide synergistic co-stimulation of CD40 on antigen presenting cells and simultaneously block the PD-1/PD-L1 inhibitory pathway Simultaneously engage
Slide 16: ADAPTIR and ADAPTIR-FLEX Platforms
ADAPTIR ADAPTIR-FLEX Drug Targeting Binds up to two targets Binds up to four targets Genetic and Structural Format Single gene that assembles into a homodimer based on an antibody backbone Two genes that assemble into a heterodimer with a knob-in-hole antibody backbone Half-life Contains Immunoglobu
Slide 17: The Company
Bispecifics Differentiated by Design ™ Therapeutics The Company
Slide 18: Experienced & Expert Leadership
Experienced & Expert Leadership Extensive R&D, manufacturing, clinical and financial background Senior Management Marvin White, President & CEO Jeff Lamothe, Chief Operating Officer Daphne Taylor, Chief Financial Officer SoYoung Kwon, General Counsel, Business Development & Corporate Affairs Dirk Hu
Slide 19: Aptevo Therapeutics: Bispecifics Differentiated by Design
Aptevo Therapeutics: Bispecifics Differentiated by Design Multi-Billion-Dollar Opportunities Assets that specifically target high-value oncology indications in multi-billion-dollar underserved markets Rationally Designed Assets Bispecifics that are engineered for optimal immune engagement delivering
Slide 20: Appendix
Bispecifics Differentiated by Design ™ Therapeutics Appendix
Slide 21: Novel Bispecific Mipletamig for AML, MDS & Other Leukemias
Novel Bispecific Mipletamig for AML, MDS & Other Leukemias POTENTIAL INDICATIONS Multiple blood cancers, including frontline and relapsed/refractory AML and MDS Combinable with standard of care (venetoclax & azacitidine) with demonstrated improved patient outcomes UNIQUE DESIGN Designed to engage T
Slide 22: Why We are Targeting CD123
Why We are Targeting CD123 CD123 (an IL3 receptor which creates an anchor for our unique CD3) is an antigen that is overexpressed in AML and MDS cells which makes this a meaningful therapeutic target CD123 is also expressed on leukemic stem cells (LSCs), which are self-renewing, making them resistan
Slide 23: Dose Escalation Trial: Safety Results
Dose Escalation Trial: Safety Results are Compelling and Promising Of the 90 patients treated with mipletamig, only 27% experienced CRS 7% of patients had CRS cases grade 3 or higher Side effects were generally manageable in the clinic Incidence of CRS Dose Escalation Dose Expansion Total # Patients
Slide 24: Dose Escalation Trial: Efficacy Outperforms Benchmarks
Dose Escalation Trial: Efficacy Outperforms Benchmarks *Benchmark Composite References: Aldoss 2019, Maiti 2021, Morsia 2020, Garciaz 2022, Feld 2021. CR: Complete remission, CRi: Complete remission with incomplete hematologic recovery, MLFS: Bone marrow complete remission, SD: Stable disease, CBR:
Slide 25: 100% Remission Among Frontline Patients Across Two Trials
100% Remission Among Frontline Patients Across Two Trials 100% composite remission rate and 71% CR rate Nearly double the benchmark for most key outcomes 100% remission rate for patients with TP53 genetic mutation (generally known to have poor prognosis) * all frontline patients dosed in combination
Slide 26: Dose Escalation Trial: Encouraging Duration of Remission
Dose Escalation Trial: Encouraging Duration of Remission (DOR) Multiple patients moved to transplant - 3/11 patients responded sufficiently to move to stem cell transplant – receiving stem cell transplant is the treatment option with the best probability for survival and highest benefit to patients
Slide 27: Monotherapy Trial Laid the Foundation
Monotherapy Trial Laid the Foundation: Evidence of Single Agent Activity in Dose Escalation and Expansion Studies Mipletamig was explored in the dose escalation study as a single agent. Given the evidence of AML blast cell reduction as well as clinical benefit in a heterogenous and difficult to trea
Slide 28: Novel Bispecific ALG.APV-527 for Multiple Solid Tumors
Novel Bispecific ALG.APV-527 for Multiple Solid Tumors POTENTIAL INDICATIONS Multiple solid tumor cancers, including lung, breast, head & neck, colorectal, pancreatic, and other solid tumors with significant markets Unique Design Unique mechanism of action allows for targeting of both 4-1BB (co-stim
Slide 29: Why We are Targeting 4-1BB + 5T4
Why We are Targeting 4-1BB + 5T4 4-1BB provides attributes to T cells and NK cells that enhance tumor cell killing 4-1BB is one of many costimulatory receptors expressed on tumor infiltrating T cells and NK cells but not on peripheral blood cells, allows for precision targeting of tumor cells 5T4 is
Slide 30: Thank You
Thank You Aptevo Therapeutics Inc. 2401 4th Avenue, Suite 1050 Seattle, WA 98121 General Inquiries Tel: 206-838-0500 Fax: 206-838-0503 Investor Relations & Communications Miriam Weber Miller Tel: 206-859-6628 Email: ir@apvo.com or Millerm@apvo.com
Aptevo Therapeutics — Investor Presentation (February 2025) on 6ix